Brain

Brain Cancer Canada Matches Community Fundraising to Support Groundbreaking DIPG Research

TORONTO, May 17, 2023 (GLOBE NEWSWIRE) -- Brain Cancer Canada (BCC), a leading advocate in the fight against brain cancers,…

1 year ago

Evox Therapeutics Granted Key US Exosome Purification Patent to Further Expand Its Leading Patent Portfolio

Newly issued US patent covers key step in the exosome manufacturing processOXFORD, United Kingdom, May 17, 2023 (GLOBE NEWSWIRE) --…

1 year ago

Achieve Life Sciences Announces Refinancing of Outstanding Loan with Silicon Valley Bank

Refinanced Loan Extends Maturity to December 2024SEATTLE and VANCOUVER, British Columbia, May 17, 2023 (GLOBE NEWSWIRE) -- Achieve Life Sciences,…

1 year ago

IN8bio’s DeltEx Gamma-Delta T Cells Show Promise in Targeting Ovarian Cancer

Preclinical results showcase the potential for the strong synergistic combination of chemotherapy and gamma-delta T cell therapy to target solid…

1 year ago

BrainsWay Reports First Quarter 2023 Financial Results and Operational Highlights

BURLINGTON, Mass. and JERUSALEM, May 17, 2023 (GLOBE NEWSWIRE) -- BrainsWay Ltd. (NASDAQ & TASE: BWAY) (“BrainsWay” or the “Company”),…

1 year ago

Clene Reports First Quarter 2023 Financial Results and Recent Operating Highlights

ALS biomarker and long-term clinical data expected mid-yearNeurology expert Ben Greenberg, M.D., M.H.S., joined as Head of MedicalSALT LAKE CITY,…

1 year ago

Impel Pharmaceuticals Announces First Quarter 2023 Financial Results and Provides Business Update

Trudhesa® Achieved nTRx of Over 18.5K in Q1 2023; Increase of 112% vs. Q1 2022 Trudhesa Net Product Revenue in…

1 year ago

Evox Therapeutics Presents Progress Across its DeliverEX® Platform Highlighting Advances in Exosome-Mediated Delivery of Genetic Medicines Including Gene Editing and RNA Therapeutics

Six Upcoming Presentations at the Annual Meetings of the American Society of Gene and Cell Therapy (ASGCT) and of the…

1 year ago

IN8bio Reports First Quarter 2023 Financial Results and Provides Corporate Update

Presented positive INB-100 data showing long-term complete remissions (CR) and elevated gamma-delta T cell levels in 100% of evaluable treated…

1 year ago

Longeveron Inc. Provides Corporate Update and Reports First Quarter 2023 Financial Results

-- New long-term survival data disclosed from ELPIS I trial of Lomecel-BTM for Hypoplastic Left Heart Syndrome; Data reinforce potential…

1 year ago